William G. Wierda - Concepedia

Author

William G. Wierda

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Carsten U Niemann, Tannous, Bakhos, W G Wierda, W WIERDA, W Wierda, W. G Wierda, W. G. Wierda, W. WIERDA, W. Wierda, W.G. Wierda

1.5K

Publications

61.9K

Citations

120

H-Index

153

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute University of California San Diego University of California, Irvine The Ohio State University

About

William G. Wierda is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	143	13.1K
2	Health Sciences	28	49	4.9K
3	Engineering	1	1	117
4	Natural Sciences	1	1	13
5	Public Health	1	1	170

William G. Wierda

527

Publications

55.1K

Citations

117

H-Index

Page 1

	Year	Citations
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Richard R. Furman, Steven Coutré, New England Journal of Medicine	2013	2.2K
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors Enli Liu, David Marín, Pinaki P. Banerjee, New England Journal of Medicine	2020	2K
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia Andrew W. Roberts, Matthew S. Davids, John M. Pagel, New England Journal of Medicine	2015	1.8K
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Bonnie K. Harrington, Susan O’Brien, New England Journal of Medicine	2015	878
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease Andrew W. Roberts, John F. Seymour, Jennifer R. Brown, Journal of Clinical Oncology	2011	808
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyHematology	2016	783
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity E Liu, Yijiu Tong, Gianpietro Dotti, Leukemia Cell TherapyCancer ImmunosurveillanceImmunologyPotent Antitumor ActivityImmunologic Mechanism	2017	778
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Matthew S. Davids, Andrew W. Roberts, John F. Seymour, Journal of Clinical Oncology ImmunologyPathologyPharmacotherapyFirst-in-human StudyImmunotherapy	2017	737
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Bijal Shah, Armin Ghobadi, Olalekan O. Oluwole, The Lancet Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyHematology	2021	721
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Constantine S. Tam, Susan O’Brien, William G. Wierda, Blood	2008	687

Page 1